secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001104659-24-046099
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech secures $5M convertible loan; issues warrant and conversion shares at $2.00
--------------------------------------------------------------------------------

- Closed two tranches totaling $5M: $1M on April 8 and $4M on April 9, 2024.
- Convertible note with conversion price $2.00/share; warrant for up to 1,000,000 shares at $2.00.
- Interest rate tied to EWB credit or SOFR+2.85%, floor 7.5%; matures Oct 4, 2026.
- Proceeds to fund Alzheimer's Phase 2 and Parkinson's Phase 1/2a trials; reduced monthly burn by ~50%.
- Company to seek shareholder approval for share issuance under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000110465924046099/0001104659-24-046099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000110465924046099/tm2411469d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer